---
layout: default
title: Pembrolizumab
parent: 僅模型預測 (L5)
nav_order: 536
evidence_level: L5
indication_count: 10
---

# Pembrolizumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Pembrolizumab: From Advanced Malignancies (PD‑1 Immunotherapy) to Gingival Fibromatosis

## One-Sentence Summary

Pembrolizumab (DrugBank DB09037) is an anti‑PD‑1 immune checkpoint inhibitor used across multiple advanced malignancies; the specific NPRA/Malaysia-approved indication text was not captured in this evidence pack. The TxGNN model's top-ranked new-indication prediction is **Fibromatosis, Gingival** (a benign gum fibrous overgrowth), but this candidate has **zero supporting clinical trials and zero literature**, and the evidence pack's own mechanistic review finds no biological link to PD‑1 blockade — the high score most likely reflects graph-embedding noise rather than a genuine repurposing signal.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not extracted from Malaysia NPRA license text (data gap DG001/DG002); pembrolizumab is a PD‑1 checkpoint inhibitor used in advanced malignancies (melanoma, NSCLC, MSI‑H colorectal cancer, HNSCC, hepatocellular carcinoma, etc.) per drug class and cited literature |
| Predicted New Indication | Fibromatosis, gingival |
| TxGNN Prediction Score | 99.40% |
| Evidence Level | L5 |
| Malaysia Market Status | 已上市 (Marketed) |
| Number of Registrations | 1 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (DG002: Blocking gap on DrugBank MOA query). Based on known information, pembrolizumab is a humanized IgG4 monoclonal antibody that blocks the PD‑1 receptor, restoring T‑cell activity against tumor cells expressing PD‑L1; its efficacy in various advanced malignancies is well established mechanistically and in the wider literature referenced throughout this evidence pack.

However, for this specific candidate, the prediction is **not reasonable**. Gingival fibromatosis is a benign, non‑neoplastic fibrous gum overgrowth disorder — it does not involve tumor neoantigen presentation, immune evasion, or any known PD‑1/PD‑L1 axis biology. The evidence pack's own rationale states explicitly: *"non-immune-evasion/neoantigen mechanism; no known biological connection to PD‑1 checkpoint blockade. The high TxGNN score likely reflects knowledge-graph proximity noise rather than an explainable mechanism."*

No clinical trials or publications were retrieved linking pembrolizumab to gingival fibromatosis, further confirming this is a model-artifact prediction rather than a substantiated repurposing hypothesis.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

Please refer to the package insert for safety information. (No key warnings, contraindications, or drug-interaction data were retrieved for this candidate; DG001 flags this as a Blocking gap that prevents formal S1 safety screening.)

---

## Cytotoxicity

Pembrolizumab is an antineoplastic agent (immune checkpoint inhibitor class, used across multiple malignancies per cited literature), so this section applies.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Immunotherapy (anti‑PD‑1 checkpoint inhibitor) — not a conventional cytotoxic chemotherapeutic |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Standard checkpoint‑inhibitor monitoring: CBC with differential, liver and renal function, thyroid/endocrine panel, and clinical surveillance for immune-related adverse events |
| Handling Protection | Please refer to the package insert warnings and precautions; as a biologic monoclonal antibody it does not fall under conventional cytotoxic (chemotherapy) handling regulations, but institutional biologic-handling SOPs should apply |

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
- The rank‑1 candidate has an L5 evidence level (model prediction only), zero trials, zero literature, and an explicit negative mechanistic assessment already recorded in the evidence pack. Across all 10 candidates in this batch, scores are nearly indistinguishable (99.27%–99.40%), most evidence retrieved is either irrelevant (mismatched to unrelated benign/rare-disease ontology terms) or actually describes pembrolizumab's *existing* approved oncology indications rather than the predicted new one — none reach evidence level L1–L3.
- DG001 (TFDA/NPRA warnings and contraindications, Blocking severity) means this candidate cannot yet clear S1 safety screening regardless of efficacy signal.

**To proceed, the following is needed:**
- Resolve DG001 (Blocking): retrieve NPRA label warnings/contraindications before any S1 safety evaluation.
- Resolve DG002 (High): confirm mechanism of action via DrugBank API to support/refute mechanistic plausibility claims.
- Confirm the Malaysia-approved indication text (current license record is empty despite 1 registered product).
- If a viable repurposing signal is the goal, consider re-examining rank 4 ("lung hilum carcinoma," L4/S1, "Research Question") instead — it is the only candidate in this batch with anatomically plausible NSCLC-adjacent biology, though its current literature is limited to adverse-event case reports rather than efficacy data.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

